Taysha Will Present Rett Syndrome Trial Data in Montréal
The company will share investigational gene therapy trial results at the 55th Child Neurology Society Annual Meeting.
Updated on Oct. 1, 2026 in Autism
Live Poll
Do you trust that pharmaceutical companies provide sufficient transparent updates on clinical trial progress?
Taysha Gene Therapies will present data on its TSHA-102 investigational gene therapy for Rett syndrome in Montréal from October 14 to October 17, 2026. These encore presentations follow findings shared at the 2026 International Rett Syndrome Foundation Scientific Meeting.
Why it matters
The program addresses a condition currently lacking any approved disease-modifying therapies for the 15,000 to 20,000 patients affected across the U.S., EU, and U.K. TSHA-102 works by delivering a functional MECP2 gene to the central nervous system.
TSHA-102 is an investigational AAV9 gene transfer therapy utilizing miRNA-Responsive Auto-Regulatory Element technology to regulate MECP2 levels in the brain. There are currently no approved disease-modifying therapies for the disorder.
The players
Taysha Gene Therapies
This biotechnology company is based in Dallas and specializes in developing adeno-associated virus-based gene therapies for severe monogenic diseases.
The details
Taysha Gene Therapies is scheduled to present results from its REVEAL Phase 1/2 trial on October 15, 2026. The company will also hold a symposium on October 16 to discuss the technology, which aims to provide a functional form of the MECP2 gene to affected cells.
Timeline
October 14-17, 2026: The 55th Child Neurology Society Annual Meeting takes place in Montréal.
October 15, 2026: Taysha will present REVEAL Phase 1/2 trial data.
October 16, 2026: Taysha will host a scientific symposium.
The Big Picture
The REVEAL Phase 1/2 trial serves as the foundational research benchmark for evaluating the clinical efficacy of TSHA-102 in treating Rett syndrome. This progress reflects a broader industry movement toward using AAV9-based gene transfer to address neurodevelopmental disorders.
For families affected by Rett syndrome, this trial update represents the potential for future access to a therapeutic option where none currently exists. Readers should monitor clinical trial progress as there are no disease-modifying treatments available for patients today.
The takeaway
Clinical trial milestones like the REVEAL program are critical for navigating the path toward regulatory approval for rare genetic conditions. Families should consult with their healthcare providers regarding emerging trial opportunities as research in gene therapy continues to evolve.
Further reading
Learn more about the latest research and clinical developments in our Autism section.
Live Poll
Do you trust that pharmaceutical companies provide sufficient transparent updates on clinical trial progress?
